MDT · a US exchange · USD · Market cap $118.2B · 95,000 employees
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
Screened 2026-09-08 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Medtronic holds its Markup at $92.39. Elevated stress, defensive posture warranted, held for 9 days.
As held on the ledger · 2026-09-08
Phase
Markup
Quantitative state
Elevated stress, defensive posture warranted, held for 9 days
Price at the screen
$92.39
Valuation
22.76 trailing · 14.44 forward price to earnings
Values screen
PASS· score 83.0
Beta
0.57
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
31.10%
Below 33%
Interest-bearing debt is just 31.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
7.36%
Below 33%
Cash held in interest-bearing accounts and securities is 7.4% of assets, under the one-third limit.
Pass
Receivables
9.53%
Below 49%
Money owed to the company is 9.5% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 31% discount to our $121.00 fair value, narrow competitive moat, 13.70% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 31.0% margin of safety to the base estimate.
Third-party analyst targets: 25 covering, consensus Buy. The average target sits +15% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
Picturing a remote village in Ireland, a pacemaker from Medtronic could mean the difference between life and death. This is no exaggeration, as Medtronic's device-based medical therapies span from implantable pacemakers to advanced surgical equipment, proving essential in healthcare systems globally. Why it stands out is evident in its fair value of $120.51 against its current price of $92.30, presenting a significant margin of safety of +31%, with a forward P/E of 14.4x, reflecting a market undervaluation of this ethically scrutinized and cleared medical titan.
The numbers tell a compelling story: a 10% revenue growth and a 13% profit margin are solid, though the ROE of 10% and a narrow moat suggest this isn't a runaway leader but a steady performer. With 25 analysts chiming in with a consensus buy rating and a median target of $100, the market's lukewarm sentiment stands in stark contrast to the robust ethical and financial profile Medtronic presents. Risks are inherent in any medtech investment, including regulatory hurdles and the ever-present need for innovation to stay competitive, yet Medtronic clears our ethical screen, aligning with our principles.
The risks · The things to watch: its business and earnings are exposed to Ireland and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MDT trades on a US exchange (the company is based in Ireland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-18Markup$85.99+0.0%Entry 11
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-16Markup$85.99+0.0%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-15Markup$85.99+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-14Markup$85.99+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-13Markup$85.99+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-12Markup$85.99+0.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-11Markup$85.99+3.3%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-05Markup · changed$83.21+1.9%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107.
2026-07-18Distribution$81.67+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107.
2026-07-03Distribution$81.67+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
